Emcure Pharma strengthens the board of directors.Added Independent Director

New Delhi, July 27, 2021:

Emcure Pharmaceuticals Ltd., one of India’s leading pharmaceutical companies, continues to strengthen its leadership by appointing prominent experts to its board of directors. The company recently added four independent directors with extensive knowledge and experience in a variety of areas.

The new additions are Dr. Sheresh Eyanger, Mr. Vijay Gokale, Mr. Hitesh Jain, and Dr. Vidia Jerafdekar, who became Chairman of the Emcure Board earlier this year. Since 1997, the company has a long tradition of appointing a chairman from among independent directors.

Emcure aims to further strengthen its strengths as one of India’s fastest growing pharmaceutical companies with global reach to more than 70 countries around the world. These additions to Emcure Pharmaceuticals’ leadership team reflect our commitment to enrich our expertise and strengthen our business for future growth. The combined strength of new members across law, pharmaceuticals, policymaking and academics provides additional impetus for Emcure’s growth trajectory.

Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, said of the appointment: The experience of new members and a broader perspective from their respective disciplines will play an important role in strengthening strategic operations to grow in the domestic and international markets. It’s an exciting time for the organization and we look forward to achieving new heights with the addition of new members. “

About the new president and additional board members:

Berjis Desai Emcure’s Chairman and Independent Director has been associated with Emcure Pharmaceuticals for over 30 years. Having practiced trading and dispute resolution for the past 37 years, Desai has retired from JSA’s managing partner, a national law firm. He holds a Master of Laws (first starring) from the University of Cambridge and is now an independent legal advisor engaged in private client practices. Former journalist Desai is a part-time writer and columnist.

Dr. Shailesh Ayyangar, appointed as additional director, has 34 years of extensive experience in healthcare and pharmaceuticals. Dr. Ayyangar was Managing Director of his latest mission in Sanofi and was a member of the International Leadership Team and Country Chair in India and South Asia. For nearly 18 years, he has been involved in all of the Sanofi Group’s businesses, including pharmaceuticals, specialty care, vaccines, animal health and consumer health care. Prior to joining Sanofi in 2002, Dr. Ayyangar held senior positions at SmithKline Beecham Pharmaceuticals and GSK in India and the United Kingdom for 14 years. On the health side, Dr. Ayyangar builds innovative partnerships such as Apollo Sugar Clinics, one of the country’s longest-serving country chairs, and engages in global and domestic M & A activities. It helped to put it together.

Appointed as Independent Director, Vijay Gokarley has been working for the Indian Foreign Service since 1981. Mr. Go Curry’s previous diplomatic missions include his presence in Hong Kong, Hanoi, Beijing and New York. He also served as Deputy Secretary (Finance), Director (China and East Asia) and Co-Secretary (East Asia) during his term at the Ministry of Foreign Affairs headquarters. His geopolitical perspective brings an additional dimension to Emcure’s future outlook.

Hitesh Jain, appointed Independent Director, is a graduate of the London School of Economics in 1996. He is a managing partner of Parinam Law Associates. His work spans 24 years of experience spanning clients in all departments of litigation and in multiple sectors. He has represented clients such as the Supreme Court of India, various High Courts of India, district courts (civil, criminal and leasing law issues), consumer forums, competition committees and TDSAT. He has advised clients on a variety of issues, including international companies. Commerce, banking, labor issues, and mergers and acquisitions. He also advises companies on the issuance and trading of securities in the primary and secondary markets.

Dr. Vidya Yeravdekar, appointed as an independent director, is the principal of the Symbiosis Society and the professional prime minister of the Symbiosis International University. Among her various praises and achievements include: Chairman of the FICCI Higher Education Committee and a member of the Indian Brand Equity Foundation (IBEF) Trust established by the Government of the Chamber of Commerce. A member of the Central Governance Council of the Service Export Promotion Council (SEPC) established by the Ministry of Commerce and Industry of India. Above all, of India.

Dr. Yeravdekar holds a graduate degree in medicine, a degree in law, and a PhD. In “Internationalization of Higher Education in India”. ET Health World